We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 18.00 | 0.16% | 11,268.00 | 11,222.00 | 11,226.00 | 11,362.00 | 11,220.00 | 11,250.00 | 3,556,178 | 16:35:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 29.21 | 173.96B |
From Apr 2019 to Apr 2024
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug Administration had awarded its cancer drug Imfinzi orphan drug status as a treatment for small-cell lung cancer.
The designation is given to medicines that aim to treat rare diseases and provides benefits such as market exclusivity and faster regulatory approvals.
Imfinzi is currently approved as a treatment for inoperable stage 3 non-small-cell lung cancer after chemotherapy and radiation therapy.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
July 12, 2019 02:31 ET (06:31 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
